Business StrategyThe sale of DERMAdoctor should reduce its cash burn and allows it to focus on pursuing newer and stronger growth opportunities that are better aligned with its core eyecare business.

Bears Say

Financial PerformanceNet loss was $1.6 million or EPS of $(1.37) compared with our estimates of $(1.28) and consensus of $(1.23).

Investor UncertaintyThe company did not provide 2024 guidance, which creates uncertainty for investors.

Revenue PerformanceRevenue was $2.4 million compared with our estimates of $2.8 million and consensus of $3.2 million.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

17.05%

Insiders

0.56% Mutual Funds

5.00% Other Institutional Investors

77.39% Public Companies and Individual Investors

Detailed Ownership Overview >

NBY FAQ

What was Novabay Pharmaceuticals’s price range in the past 12 months?

Novabay Pharmaceuticals lowest stock price was $0.36 and its highest was $2.45 in the past 12 months.

What is Novabay Pharmaceuticals’s market cap?

Novabay Pharmaceuticals’s market cap is $3.52M.

When is Novabay Pharmaceuticals’s upcoming earnings report date?

Novabay Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is in 38 days.

How were Novabay Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Novabay Pharmaceuticals overvalued?

According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novabay Pharmaceuticals pay dividends?

Novabay Pharmaceuticals does not currently pay dividends.

What is Novabay Pharmaceuticals’s EPS estimate?

Novabay Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Novabay Pharmaceuticals have?

Novabay Pharmaceuticals has 5,816,204 shares outstanding.

What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Novabay Pharmaceuticals?

Currently, no hedge funds are holding shares in NBY

Company Description

Novabay Pharmaceuticals

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.